Senior Manager, Clinical Scientist, Oncology
Regeneron Pharmaceuticals
Summary
Regeneron Pharmaceuticals is a leading American biotechnology company founded in 1988 and headquartered in Tarrytown, New York. The company specializes in inventing, developing, and commercializing life-transforming medicines for people with serious diseases. Regeneron is renowned for its innovative antibody technologies and has developed several groundbreaking therapies, including EYLEA® for retinal diseases, DUPIXENT® for inflammatory conditions, and the COVID-19 antibody cocktail REGEN-COV®. The company operates with a strong focus on research and development across multiple therapeutic areas including ophthalmology, oncology, cardiovascular diseases, and rare genetic disorders. Regeneron's proprietary VelocImmune® technology platform enables the rapid generation of fully human monoclonal antibodies. With over 15,000 employees globally and annual revenues exceeding $14 billion, Regeneron has established itself as a major force in the biotechnology industry, consistently ranking among the top-performing pharmaceutical companies and maintaining a robust pipeline of investigational therapies.
Job description
Discover your role
- Lead the planning and execution of clinical studies across early and late phase oncology programs
- Partner with Medical Directors to bring scientific expertise to study and program design
- Contribute to protocol development, including the Expanded Synopsis and clinically relevant sections
- Author and review study documents such as medical monitoring plans, SAPs, informed consents and clinical sections of study reports
- Perform clinical and medical data review to safeguard patient safety and data integrity
- Build deep knowledge of the disease area, mechanism of action and drug landscape
- Connect study design to data analysis to identify critical risks and mitigations
- Influence and collaborate across a matrix of cross-functional teams, advisory boards and safety monitoring groups
This role requires
- Bachelor's degree required; advanced degree in life science/healthcare preferred (PhD, MD, PharmD, MSc)
- 8+ years of pharmaceutical clinical drug development experience
- Proven knowledge of the drug development process, GCP, ICH guidelines, study design and clinical research methodology
- Strong medical writing skills
- Demonstrated ability to influence within and across teams, with clear communication and strong presentation skills
- Strong analytical, interpersonal and problem-solving skills, including independently resolving complex issues
- Proven track record of clinical trial process improvements
- Significant experience working cross-functionally with strong organizational awareness
- Other levels may be considered depending on experience
Requirements
- Bachelor's degree required
- Advanced degree in life science/healthcare preferred (PhD, MD, PharmD, MSc)
- 8+ years of pharmaceutical clinical drug development experience
- Proven knowledge of the drug development process, GCP, ICH guidelines, study design and clinical research methodology
- Strong medical writing skills
- Demonstrated ability to influence within and across teams
- Clear communication and strong presentation skills
- Strong analytical, interpersonal and problem-solving skills
- Independently resolving complex issues
- Proven track record of clinical trial process improvements
- Significant experience working cross-functionally
- Strong organizational awareness
Benefits
- Annual bonuses
- Incentive plans
- Equity awards
- Pension or retirement benefits
- 401(k) company match
- Health and wellness programs
- Fitness centers
- Insurance benefits
- Paid time off
- Family support benefits
Company overview
Regeneron Pharmaceuticals is a leading American biotechnology company founded in 1988 and headquartered in Tarrytown, New York. The company specializes in inventing, developing, and commercializing life-transforming medicines for people with serious diseases. Regeneron is renowned for its innovative antibody technologies and has developed several groundbreaking therapies, including EYLEA® for retinal diseases, DUPIXENT® for inflammatory conditions, and the COVID-19 antibody cocktail REGEN-COV®. The company operates with a strong focus on research and development across multiple therapeutic areas including ophthalmology, oncology, cardiovascular diseases, and rare genetic disorders. Regeneron's proprietary VelocImmune® technology platform enables the rapid generation of fully human monoclonal antibodies. With over 15,000 employees globally and annual revenues exceeding $14 billion, Regeneron has established itself as a major force in the biotechnology industry, consistently ranking among the top-performing pharmaceutical companies and maintaining a robust pipeline of investigational therapies.